PCSK9 Concentrations in Cerebrospinal Fluid Are Not Specifically Increased in Alzheimer’s Disease

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

(2017) Robert P Giugliano et al.   LANCET

Diagnosis and management of dementia with Lewy bodies

(2017) Ian G. McKeith et al.   NEUROLOGY

Cognitive Function in a Randomized Trial of Evolocumab

(2017) Robert P. Giugliano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term Low-Density Lipoprotein Cholesterol–Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia

(2017) Michael J. Koren et al.   JAMA Cardiology

Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials

(2016) Michel Farnier et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer’s Disease

(2016) Francesca Zimetti et al.   JOURNAL OF ALZHEIMERS DISEASE

High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer’s disease

(2016) Malin Degerman Gunnarsson et al.   Alzheimers Research & Therapy

Role of PCSK9 beyond liver involvement

(2015) Bertrand Cariou et al.   CURRENT OPINION IN LIPIDOLOGY

Endothelial LRP1 transports amyloid-β1–42 across the blood-brain barrier

(2015) Steffen E. Storck et al.   JOURNAL OF CLINICAL INVESTIGATION

Identification of PCSK9 as a novel serum biomarker for the prenatal diagnosis of neural tube defects using iTRAQ quantitative proteomics

(2015) Dong An et al.   Scientific Reports

PCSK9

(2014) Nabil G. Seidah et al.   CIRCULATION RESEARCH

PCSK9 is Present in Human Cerebrospinal Fluid and is Maintained at Remarkably Constant Concentrations Throughout the Course of the Day

(2014) Yan Q. Chen et al.   LIPIDS

Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets

(2013) Bertrand Cariou et al.   Nutrition & Metabolism

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)

(2013) Maryssa Canuel et al.   PLoS One

PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling

(2012) Kai Kysenius et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Guy M. McKhann et al.   Alzheimers & Dementia

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia

(2011) Katya Rascovsky et al.   BRAIN

PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke

(2011) Estelle Rousselet et al.   JOURNAL OF LIPID RESEARCH

The Multiple Phenotypes of Corticobasal Syndrome and Corticobasal Degeneration: Implications for Further Study

(2011) Bradley F. Boeve   JOURNAL OF MOLECULAR NEUROSCIENCE

Classification of primary progressive aphasia and its variants

(2011) M. L. Gorno-Tempini et al.   NEUROLOGY

PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain

(2010) Mali Liu et al.   JOURNAL OF LIPID RESEARCH

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

(2010) Kaj Blennow et al.   Nature Reviews Neurology

CSF biomarkers predict a more malignant outcome in Alzheimer disease

(2010) A. K. Wallin et al.   NEUROLOGY

CSF biomarkers predict rate of cognitive decline in Alzheimer disease

(2009) M. I. Kester et al.   NEUROLOGY

PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1

(2008) Mary Cabell Jonas et al.   EMBO REPORTS